Baird Financial Group
CSTL icon

Baird Financial Group’s Castle Biosciences CSTL Stock Holding History

Baird Financial Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,455
Closed -$260K – 1700
2023
Q1 		$260K Sell
11,455
-739
-6% -$18.1K ﹤0.01% 1534
2022
Q4 		$287K Sell
12,194
-155
-1% -$3.59K ﹤0.01% 1469
2022
Q3 		$322K Sell
12,349
-1,397
-10% -$39.2K ﹤0.01% 1437
2022
Q2 		$302K Sell
13,746
-603
-4% -$14K ﹤0.01% 1554
2022
Q1 		$644K Buy
14,349
+674
+5% +$27.9K ﹤0.01% 1315
2021
Q4 		$586K Sell
13,675
-366
-3% -$19.1K ﹤0.01% 1412
2021
Q3 		$934K Buy
14,041
+1,448
+11% +$102K ﹤0.01% 1226
2021
Q2 		$923K Buy
12,593
+230
+2% +$15.2K ﹤0.01% 1209
2021
Q1 		$846K Buy
12,363
+787
+7% +$59.2K ﹤0.01% 1186
2020
Q4 		$777K Buy
11,576
+1,884
+19% +$102K ﹤0.01% 1095
2020
Q3 		$499K Buy
+9,692
New +$431K ﹤0.01% 1152

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baird Financial Group's CSTL Position: Q2 2023 in Review

Baird Financial Group sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 11,455 shares — an estimated $260K sold.

Baird Financial Group first reported a position in CSTL in Q3 2020 and held it in 11 quarters. The position peaked at $934K in Q3 2021. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • Baird Financial Group reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • Baird Financial Group sold 11,455 Castle Biosciences shares in Q2 2023, an estimated $260K.
  • Baird Financial Group first reported a position in Castle Biosciences in Q3 2020 and held it in 11 quarters.
  • Baird Financial Group's Castle Biosciences position peaked at $934K in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Baird Financial Group's 13F filing for Q2 2023, filed 11 Aug 2023.